Early emergence of PNH-like T cells after allogeneic stem cell transplants utilising CAMPATH-1H for T cell depletion
Early emergence of PNH-like T cells after allogeneic stem cell transplants utilising CAMPATH-1H for T cell depletion
复制标题
利用 CAMPATH-1H 消除 T 细胞，同种异体干细胞移植后早期出现 PNH 样 T 细胞
DOI：
--
复制
发表时间：
2005
影响因子：
4.8
通讯作者：
C. Steward
中科院分区：
文献类型：
--
作者：
R. Garland;S. Groves;P. Diamanti;S. E. West;K. L. Winship;P. Virgo;S. Robinson;A. Oakhill;J. Cornish;D. Pamphilon;D. Marks;N. Goulden;C. Steward
总结：CAMPATH-1H（C-1H）广泛用于造血SCT中的体内和/或体外T细胞耗竭。这种人源化单克隆抗体对CD 52具有特异性，CD 52是一种在大多数人淋巴细胞上与CD 48和其他糖基磷脂酰肌醇（GPI）锚定蛋白共表达的标志物。我们检测到CD 52/CD 48双表达>99%的CD 3+淋巴细胞来自正常个体和所有15个SCT后患者，其移植不利用C-1H。相比之下，23 / 26例涉及C-1H（体内、体外或两者）移植的患者表现出缺乏CD 52表达的群体，占SCT后中位时间2个月评价的样本中CD 3+淋巴细胞（中位数和范围）的49.7%（4.2-86.2%）。大多数CD 52 −细胞也缺乏CD 48表达。这些GPI-T细胞来自供体或混合供体/受体来源。在SCT后的最初几个月，在淋巴细胞严重减少的时候，它们是主要的，并且与绝对淋巴细胞计数的恢复呈负相关（r=-0.663，P<0.0001）。CD 52 −细胞的存在与CAMPATH治疗恶性和非恶性疾病后的临床结果相关。
Summary:CAMPATH-1H (C-1H) is widely used in vivo and / or in vitro for T cell depletion in hematopoietic SCT. This humanised monoclonal antibody is specific for CD52, a marker coexpressed on the majority of human lymphocytes with CD48 and other glycosylphosphatidyl-inositol (GPI) anchored proteins. We detected CD52 / CD48 dual expression on >99% of CD3+ lymphocytes from normal individuals and all 15 post-SCT patients whose transplants did not utilise C-1H. By contrast, 23 / 26 patients with transplants involving C-1H (in vivo, in vitro or both) exhibited populations lacking CD52 expression that accounted for 49.7% (4.2–86.2%) of the CD3+ lymphocytes (median and range) in samples evaluated at a median of 2 months post-SCT. Most CD52− cells also lacked CD48 expression. These GPI− T cells were of either donor or mixed donor / recipient origin. They were predominant in the early months after SCT at times of profound lymphopenia and inversely correlated with the recovery of the absolute lymphocyte count (r= − 0.663, P<0.0001). The presence of CD52− cells has been correlated previously with clinical outcome after CAMPATH therapy for both malignant and nonmalignant diseases.